TRPV1 and neoplasm: Therefore, future therapeutic strategies should aim to restrict TRPV1 inhibition to the tumor microenvironment—for example, by using nanoparticle-mediated delivery, ligand-conjugated inhibitors, or localized ablation—to maximize efficacy while minimizing systemic adverse effects.